Food and Dietary Supplement Package Labeling-Guidance from FDA's Warning Letters and Title 21 of the Code of Federal Regulations

Comprehensive Reviews in Food Science and Food Safety

Volumn 15, Issue 1, 2016, Pages 92-129

  Brody, Tom ^a  

^a Baker Hostetler LLP (law firm)   (United States)

Author keywords

Dietary supplements; FDA; Food; Package labels

Indexed keywords

FOOD ADDITIVES; FOOD PRODUCTS; NUTRIENTS; NUTRITION; VITAMINS;

CODE OF FEDERAL REGULATIONS; COMMON SOURCE; FDA; HEALTH CLAIMS; NUTRIENT CONTENTS; STRUCTURE/FUNCTION;

DIETARY SUPPLEMENTS;

EID: 84955732399     PISSN: None     EISSN: 15414337     Source Type: Journal    
DOI: 10.1111/1541-4337.12172     Document Type: Article

References (115)

1. Hasler CM. 2008. Health claims in the United States:an aid to the public or a source of confusion. J Nutrition 138:1216S-1220S.
2. Tonkens R. May-June 2005. An overview of the drug development process. The Physician Executive. 4852.
3. DiMasi JA, Feldman L, Seckler A, Wilson A. 2010. Trends in risks associated with new drug development:success rates for investigational drugs. Clin Pharmacol Therap 87:272-7
4. Salerno RA, Lesko LJ. 2004. Pharmacogenomic data:FDA voluntary and required submission guidance. Future Med 5:503-5.
5. Rhie JK, Mauer J, Wick J, Mooney M, Ansher S, Rubenstein L, Doyle A, Schettino PR, Finnigan S, Smith, G, Hall C., Naoko Takebe N, Kruhm M, Zhang J. 2013. AHandbook for Clinical Investigators Conducting Therapeutic Clinical Trials Supported by CTEP, DCTD, NCI. Cancer Therapy Evaluation Program (CTEP), National Institutes of Health. 116 pages.
6. Brody T. 2012. Clinical Trials (Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines). Elsevier/Academic Press, p 650.
7. Rehnquist J. March 2003. FDA's Review Process for New Drug Applications. Dept. Health and Human Services.
8. Lavie CJ, Milani RV, Mehra MR, Ventuera HO. 2009 Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am College Cardiol 54:585-94.
9. Harris WS, Dayspring TD,Moran TJ. 2013. Omega-3 fatty acids and cardiovascular disease: new developments and applications. Postgrad Med 125:100- 13.
10. Harris WS, Dayspring TD, and Moran TJ. 2013. Omega-3 fatty acids and cardiovascular disease: new developments and applications. Postgrad Med 125:100-113.
11. Gordon RY, Cooperman T, Obermeyer W, and Becker DJ. 2010. Marked variability of monacolin levels in commercial red yeast products:buyer beware! Arch Intern Med 170:1722-1727.
12. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. 2009. Red yeast rice for dyslipidemia in statinintolerant patients:a randomized trial. Ann Intern Med 150:830-9.
13. American Dietetic Association. 2004. Position of the American Dietetic Association: Functional Foods. J Am Dietetic Assoc 104:814-26.
14. Schneeman B. 2007. FDA's review of scientific evidence for health claims. J Nutrition 137: 493-4.
15. Burdock GA, Carabin IG, Griffiths JC. 2006. The importance of GRAS to the functional food and nutraceutical industries. Toxicology 221:17-27.
16. Schneeman B. 2007. FDA's review of scientific evidence for health claims. J Nutrition 137:493-4.
17. Ellwood KC, Trumbo PR, Kavanaugh CJ. 2010. How the US Food and Drug Administration evaluates the scientific evidence for health claims. Nutr Rev 68:114-21.
18. Schneeman B. 2007. FDA's review of scientific evidence for health claims. J Nutrition 137:493-494.
19. Villafranco JE, Bond K. 2009. Dietary supplement labeling and advertising claims: are clinical studies on the full product required? Food and Drug Law J 64:4367.
20. Banel DK, Hu FB. 2009. Effects of walnut consumption on blood lipids and other cardiovascular risk factors: a meta-analysis and systematic review. Am J Clin Nutr 90:56-63.
21. Jenkins DJ, KendallCW, Vuksan V, Vidgen E, Parker T, FaulknerD, Mehling CC, Garsetti M, Testolin G, Cunnane SC,RyanMA, Corey PN. 2002. Soluble fiber intake at a dose approved by the US Food and Drug Administration for a claim of health benefits: serum lipid risk factors for cardiovascular disease assessed in a randomized controlled crossover trial. Am J Clin Nutr 75:834-9.
22. Gelissen IC, Brodie B, and Eastwood MA. 1994. Effect of plantago ovata (psyllum) husk and seeds on sterol metabolism:studies in normal and ileostomy subjects. Am J Clin Nutr 59:395-400.
23. Yuan JM, Sun C, Butler LM. 2011. Tea and cancer prevention: epidemiological studies. Pharmacol Res 64:123-35.
24. Bloedon LT, Szapary PO. 2004. Flaxseed and cardiovascular risk. Nutr Rev 62:18-27.
25. Bloedon, LT, Balikai S, Chittams J, Cunnane SC, Berlin JA, Rader DJ, and Szapary PO. 2008. Flaxseed and cardiovascular risk factors: results from a double blind, randomized, controlled clinical trial. J Am Coll Nutr 27:65-74.
26. Kristensen M, JensenMG, Aarestrup J, Petersen KE, Lise Søndergaard L, Mette S, Mikkelsen MS, Astrup A. 2012. Flaxseed dietary fibers lower cholesterol and increase fecal fat excretion, but magnitude of effect depend on food type. Nutri Metabolism 9:8 (8 pages).
27. Barnett JB, Hamer DH, and Meydani SN. 2010. Low zinc status: a new risk factor for pneumonia in the elderly. Nutr Rev 68:30-7.
28. U.S. Dept. Health and Human Services. Food and Drug Administration (June 3, 1996). Federal Register. 61:27771.
29. Wallace, R.J., McKain, N., Shingfield, K.J., and Devillard, E. 2007. Isomers of conjugated linoleic acids are synthesized via different mechanisms in ruminal digesta and bacteria. J. Lipid Res. 48:2247-2254.
30. Brody T. 1999. Nutritional Biochemistry. 2nd ed. San Diego, Calif.: Elsevier/ Academic Press (p 326).
31. Berger A, Jones PJ, and Abumweis SS. 2004. Plant sterols: factors affecting their efficacy and safety as functional food ingredients. Lipids Health Dis 3:5 (19 pages).
32. Brody T. 1999. Nutritional Biochemistry. 2nd ed. San Diego, Calif.: Elsevier/ Academic Press.
33. Brody T. 1999. Nutritional biochemistry, Elsevier/ Academic Press, San Diego, CA, p 521-2.
34. Food and Drug Administration. 1996. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Final Rule 21 CFR Parts 136, 137, and 139. Federal Register. 61:8781-9.
35. Crider KS, Bailey LB, Berry RJ. 2011. Folic acid food fortification-its history, effect, concerns, and future directions. Nutrients 3:370-84.
36. Hamner HC, Mulinare J, Cogswell ME, Flores AL, Boyle CA, Prue CE, Wang CY, Carriquiry AL, Devine O. 2009. Predicted contribution of folic acid fortification of corn masa flour to the usual folic acid intake for the US population: National Health and Nutrition Examination Survey 2001-2004. Am J Clin Nutr 89:305-15.
37. Quinlivan EP, Gregory JF. 2003. Effect of food fortification on folic acid intake in the United States. Am J Clin Nutr 77:221-5.
38. Hunter JE. 2006. Dietary trans fatty acids: review of recent human studies and food industry responses. Lipids 41:967-92.
39. Remig V, Franklin B, Margolis S, Kostas G, Nece T, Street JC. 2010. Trans fat in America: a review of their use, consumption, health implications, and regulation. J Am Diet Assoc 110:585-92.
40. Chardigny JM, Destaillats F, Malpuech-Brug`ere C, Moulin J, Bauman DE, Lock AL, Barbano DM, Mensink RP, Bezelgues JB, Chaumont P, Combe N, Cristiani I, Joffre F, German JB, Dionisi F, Boirie Y, Śebedio JL. 2008. Do trans fatty acids from industrially produced sources and from natural sources have the same effect on cardiovascular disease risk factors in healthy subjects? Results of the Trans Fatty Acids Collaboration (TRANSFACT) study. Am J Clin Nutr 87:558-66.
41. Brouwer IA, Wanders AJ, Katan MB. 2010. Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans - a quantitative review. PLoS ONE 5:e9434 (10 pages).
42. ASCN/AIN Task Force on Trans Fatty Acids (1996). Position paper on trans fatty acids. Am. J Clin Nutr 63:663-70.
43. Brouwer IA, Wanders AJ, Katan MB. 2010. Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans - a quantitative review. PLoS ONE 5:e9434 (10 pages).
44. Brouwer IA, Wanders AJ, and Katan MB. 2010. Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans - a quantitative review. PLoS ONE 5:e9434 (10 pages).
45. Brouwer IA, Wanders AJ, and Katan MB. 2010. Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans - a quantitative review. PLoS ONE 5:e9434 (10 pages).
46. Brouwer IA, Wanders AJ, and Katan MB. 2010. Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans - a quantitative review. PLoS ONE 5:e9434 (10 pages).
47. Schulmeister U, Hochwallner H, Swoboda I, Focke-Tejkl M, Geller B, Nystrand M, Härlin A, Thalhamer J, Scheiblhofer S, Keller W, Niggemann B, Quirce S, Ebner C, Mari A, Pauli G, Herz, U., Valenta R, Spitzauer S. 2009. Cloning, expression, and mapping of allergenic determinants of aS1casein, a major cow's milk allergen. J Immunol 182:7019-29.
48. Alessandri S, Sancho A., Vieths S, Mills CE,Wal JM, Shewry PR, Rigby N, and Hoffmann-Sommergruber K. 2012. High-throughput NME assessment of the tertriary structure of food allergens. PLoS ONE 7:e39785 (10 pages).
49. Bu G, Luo Y, Chen F, Liu K, and Zhu T. 2013. Milk processing as a tool to reduce cow's milk allergenicity: a mini review. Dairy Sci Technol 93:211-23. 29108-PHI-02. Oct. 16, 2007.
50. Gajewski KG, Hsieh YH. 2009. Monoclonal antibody specific to a major fish allergen: parvalbumin. J Food Prot 72:818-25.
51. Hajeb P, Selamat J. 2012. A contemporary review of seafood allergy. Clin. Rev. Allergy Immunol 42:365-85.
52. Lopata AL, O'Hehir RE, Lehrer SB. 2010. Shellfish allergy. Clin Exp Allergy 40:850-8.
53. Brody T, Mathews TD (1989). The release of zinc fromleukocytes provoked by A23187 and EDTA is associated with the release of enzymes. Comparative Biochem Physiol A 944: 693-7.
54. Helbling A, McCants ML, Musmand JJ, Schwartz HJ, Lehrer SB. 1996. Immunopathogenesis of fish allergy: identification of fish-allergic adults by skin test and radioallergosorbent test. Ann Allergy Asthma Immunol 77:48- 54.
55. Cantani A, Lucenti P. 1997. Natural history of soy allergy and/or intolerance in children, and clinical use of soy-protein formulas. Pediatr Allergy Immunol 8:59-74.
56. Masilamani M, Commins S, ShrefflerW. 2012. Determinants of food allergy. Immunol Allergy Clin North Am 32:11-33. 31013-PHI-18. May 30, 2013. 31110-PHI-03. Dec. 15, 2009.
57. Takahashi Y, Sasanuma T, Abe T. 2013. Accumulation of gammaaminobutyrate (GABA) caused by heat-drying and expression of related genes in immature vegetable soybean (edamame). Breed Sci 63:205-10.
58. SugimotoM, GotoH,Otomo K, ItoM,Onuma H, Suzuki A, Sugawara M, Abe S, Tomita M, Soga T. 2010. Metabolomic profiles and sensory attributes of edamame under various storage duration and temperature conditions. J Agric Food Chem 58:8418-25.
59. Wu Q, Wang M, Sciarappa WJ, Simon JE. 2004. LC/UV/ESI-MS analysis of isoflavones in edamame and tofu soybeans. J Agric Food Chem 52:2763-9.
60. Crevel RW, Kerkhoff MA, Konig MM. 2000. Allergenicity of refined vegetable oils. Food Chem Toxicol 38:385-93.
61. Hourihane JO, Bedwani SJ, Dean TP, Warner JO. 1997. Randomised, double blind, crossover challenge study of allergenicity of peanut oils in subjects allergic to peanuts. British Medical J 314:1084-8.
62. Sapone A, Bai JC, Ciacci C, Dolinsek J, Green PH, Hadjivassiliou M, Kaukinen K, Rostami K, Sanders DS, Schumann M, Ullrich R, Villalta D, Volta U, Catassi C, Fasano A. 2012. Spectrum of gluten-related disorders: consensus on new nomenclature and classification. BMC Medicine 10:13 (12 pages)
63. Sanders DS, Aziz I. 2012. Non-celiac wheat sensitivity: separating the wheat from the chat! Am J Gastroenterol 107:1908-12.
64. Pietzak M. 2012. Celiac disease, wheat allergy, and gluten sensitivity: when gluten free is not a fad. J Parentar Enteral Nutr 36(1 Suppl.):68S-75S.
65. Battais F, Richard C, Jacquenet S, Denery-Papinis S, and Moneret-Vautrin DA. 2008. Wheat grain allergies: an update on wheat allergens. Eur Ann Allergy Clin Immunol 40:67-76.
66. Tatham AS, Shewry PR. 2008. Allergens to wheat and related cereals. Clin Exp Allergy 38:1712-26.
67. Lew E, Kuzmicky DD, Kasarda DD. 1992. Characterization of low molecular weight glutenin subunits by reversed-phase high-performance liquid chromatography, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and N-terminal amino acid sequencing. Cereal Chem 69:508-15. 32610-PHI-03. Dec. 15, 2009.
68. Colomba MS, Gregorini A. 2012. The ScientificWorld J. Article ID 837416 (8 pages).
69. U.S. Dept. Health and Human Services. Food and Drug Administration (Aug. 5, 2013). Federal Register. 78:47154-79.
70. U.S. Dept. Health and Human Services. Food and Drug Administration (Jan. 5, 2009). Federal Register. 74:207-17.
71. U.S. Dept. Health and Human Services. Food and Drug Administration (Jan. 5, 2009). Federal Register. 74:207-17.
72. Brody T. 1999. Nutritional Biochemistry. 2nd ed. San Diego, Calif.: Elsevier/ Academic Press (p 821-2).
73. Nugroho AE, Riyanto S, Sukari MA, and Maeyama K (2011) Effects of aegeline, a main alkaloid of Aegle Marmelos on the histamine release from mast cells in Pak J Pharm Sci 24:359-367.
74. Abdel-Rahman A, Anyange N, Carlacci L, Casper S, Danam RP, Enongene E, Erives G, Fabricant D, Gudi R, Hilmas CJ, Hines F, Howard P, Levy D, Lin Y, Moore RJ, Pfieler E, Thurmond TS, Turujman S, and Walker NJ. 2011. The safety and regulation of natural products used as foods and food ingredients. Toxicol Sci 123:333-48.
75. Burdock GA, Carabin IG. 2004. Generally recognized as safe (GRAS): history and description. Toxicol Lett 150:3-18.
76. Burdock GA. 2000. Dietary supplements and lessons to be learned from GRAS. Regul Toxicol Pharmacol 31:68-76.
77. Neltner TG, Alger HM, O'Reilly JT, Krimsky S, Bero LA, Maffini MV. 2013. Conflicts of interest in approvals of additives to food determined to be generally recognized as safe: out of balance. JAMA Intern Med 173:2032-6.
78. American Dietetic Association. 2004. Position of the American Dietetic Association: use of nutritive and nonnutritive sweeteners. J Am Dietetic Assoc 104:255-75.
79. Hallagan JB, Hall RL. 1995. FEMA GRAS-a GRAS assessment program for flavor ingredients. Flavor and Extract Manufacturers Association. Regul Toxicol Pharmacol 21:422-30. 38337 warning letters, as determined on March 20, 2014.
80. Hallagan JB, Hall RL. 1995. FEMA GRAS-a GRAS assessment program for flavor ingredients. Flavor and Extract Manufacturers Association. Regul Toxicol Pharmacol 21:422-30.
81. Burkhardt S, Tan DX, Manchester LC, Hardeland R, Reiter RJ. 2001. Detection and quantification of the antioxidant melatonin in Montmorency and Balaton Tart cherries (Prunus cerasus). J Agric Food Chem 49:4898-902.
82. Howatson G, Bell PG, Tallent J, Middleton B, McHugh MP, Ellis J. 2012. Effect of tart cherry juice (Prunus cerasus) on melatonin levels and enhanced sleep quality. Eur J Nutr 51:909-16.
83. Gardana C, Simonetti P, Canzi E, Zanchi R, Prietta P. 2003. Metabolism of stevioside and rebaudioside A from Stevia rebaudiana extracts by human microflora. J Agric Food Chem 51:6618-22.
84. Brandle JE, Starratt AN, and Gijzen M. 1998. Stevia rebaudiana: its agricultural, biological, and chemical properties. Canadian J Plant Sci 78:527-36.
85. Abdel-Rahman A, Anyange N, Carlacci L, Casper S, Danam RP, Enongene E, Erives G, Fabricant D, Gudi R, Hilmas CJ, Hines F, Howard P, Levy D, Lin Y, Moore RJ, Pfieler E, Thurmond TS, Turujman S, and Walker NJ. 2011. The safety and regulation of natural products used as foods and food ingredients. Toxicol Sci 123:333-348.
86. Abdel-Rahman A, Anyange N, Carlacci L, Casper S, Danam RP, Enongene E, Erives G, Fabricant D, Gudi R, Hilmas CJ, Hines F, Howard P, Levy D, Lin Y, Moore RJ, Pfieler E, Thurmond TS, Turujman S, and Walker NJ. 2011. The safety and regulation of natural products used as foods and food ingredients. Toxicol Sci 123:333-48.
87. Behnen EM, Ferguson MC, and Carlson A. 2013. Do sugar substitutes have any impact on glycemic control in patients with diabetes? J Pharm Technol 29:61-5.
88. Harnly JM, Luthria D, Chen P. 2012. Detection of adulterated Ginkgo biloba supplements using chromatographic and spectral fingerprints. J AOAC Int 95:1579-87.
89. Fransen HP, Pelgrom SM, StewartKnox B, de Kaste D, Verhagen H. 2010. Assessment of health claims, content, and safety of herbal supplements containing Ginkgo biloba. Food Nutr Res 54:5221 (33 pages).
90. Lee MR. 2011. The history of Ephedra (mahuang). J R Coll Physicians Edinb 41:78-84.
91. Schaefer P, Smith J, Dahm DL, Sorenson MC. 2006. Ephedra use in a select group of adolescent athletes. J Sports Sci Med 5:407-14.
92. Seamon MJ, Clauson KA. 2005. Ephedra: yesterday, DSHEA, and tomorrow-a ten year perspective on the Dietary Supplement Health and Education Act of 1994. J Herb Pharmacother 5:67-86.
93. Seamon MJ, Clauson KA. 2005. Ephedra: yesterday, DSHEA, and tomorrow-a ten year perspective on the Dietary Supplement Health and Education Act of 1994. J Herb Pharmacother 5:67-86.
94. Gregory PJ. 2013. Availability of DMAA supplements despite US Food and Drug Administration action. JAMA Intern Med 173:164-5.
95. Schilling BK, Hammond KG, Bloomer RJ, Presley CS, Yates CR. 2013. Physiological and pharmacokinetic effects of oral 1,3-dimethylamylamine administration. Med BMC Pharmacol Toxicol 14:5261.
96. Gregory PJ. 2013. Availability of DMAA supplements despite US Food and Drug Administration action. JAMA Intern Med 173:164-5.
97. Austin KG, Travis J, Pace G, and Lieberman HR (2013). Analysis of 1,3- dimethylamylamine concentrations in Geraniaceae, geranium oil and dietary supplements. Drug Test Anal Doi: 10.1002/dta. 1491 [epub ahead of print].
98. Burdock GA, Corabin IG, Griffiths JC. 2006. The importance of GRAS to the functional food and nutraceutical industries. Toxicology 221:17-27.
99. Morgan SL, Baggott JE. 2006. Medical foods: products for the management of chronic diseases. Nutri Rev 64:495-501.
100. Scarbrough FD. 1989. Medical foods: an introduction. Food Drug Cosm 20:463-6.
101. Scarbrough FD. 1989. Medical Foods: An Introduction. Food Drug Cosm. 20:463-466.
102. U.S. Dept. Health and Human Services. Food and Drug Administration (March 3, 2014). Federal Register. 79:11880-967.
103. U.S. Dept. Health and Human Services. Food and Drug Administration (Nov. 29, 1996). Federal Register. 61:60662-71.
104. Brody T. 2012. Clinical Trials (Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines). Elsevier/Academic Press (p 415- 70).
105. Melino VJ, Soole KL, Ford CM. 2009. Ascorbate metabolism and the developmental demand for tartaric and oxalic acids in ripening grape berries. BMC Plant Biol 9:145 (14 pages).
106. Massot C, GenardM, Stevens R, Gautier H. 2010. Fluctations in sugar content are not determinant in explaining variations in vitamin C in tomato fruit. Plant Physiol Biochem 48:751-7.
107. U.S. Dept. Health and Human Services. Food and Drug Administration (July 24, 1981) Federal Register. 46:38285-308.
108. McGuffin M, Kartesz J, Leung A, Tucker A. 2000. Herbs of Commerce. American Herbal Products Association, Silver Spring, MD (442 pages).
109. Cohen PA, Venhuis BJ. 2013. Adulterated sexual enhancement supplements. JAMA Internal Med 173:1169-70. 57813-PHI-17. May 14, 2013.
110. Coleman E. 2012. Food and Drug Administration's Obesity Drug Guidance document: a short history. Circulation 125:2156-64.
111. Naber JM, Lyhus JE. 2014. October 29, Product Packaging and Labeling: An Overview of Current Legal Principles (webinar). Fitch, Even, Tabin, and Flannery LLP, Washington, D.C., 20037.
112. Liu C. 2011. Is "USDA Organic" a seal of deceit?: The pitfalls of USDA certified organic products producted in the United States, China and beyond. Stanford J. Int'l. Law. 47:333-78.
113. Watnick VJ. 2014. January 15 The Organic Foods Production Act, the process/product distinction, and a case for more end product regulation in the organic foods market. UCLA J Envt'l L Policy 32:40-79.
114. Thomas JR. 2014. The Leahy-Smith America Invents Act: Innovation Issues. Congressional Research Service.
115. Gongola J. Sept. 2014. USPTOTimelyReleases Two New AIA Reports on Virtual Marking and the Satellite Offices. United States Patent and Trademark Office.